levels

Short Trading: A comprehensive analysis of the controversial strategy and an in-depth analysis of how investors make money from market declines

Short trading is a strategy in which investors make money by taking advantage of predictions that a stock or other asset is expected to fall. The process involves borrowing shares and selling them immediately in the hope of buying them back at a lower price once their price drops, profiting from the difference between the selling and buying prices. Simply put, short trading is a way for investors to make profits through expected negative changes in the market. The Historical Origins of Short Trading The idea of ​​short trading can

[Mirror] A Proof of Stake Design Philosophy

Vitalik Buterin via the Vitalik Buterin Blog This is a mirror of the post at https://medium.com/@VitalikButerin/a-proof-of-stake-design-philosophy-506585978d51 Systems like Ethereum (and Bitcoin, and NXT, and Bitshares, etc) are a fundamentally new class of cryptoeconomic organisms — decentralized, jurisdictionless entities that exist entirely in cyberspace, maintained by a combination of cryptography, economics and social consensus. They are kind of like BitTorrent, but they are also not like BitTorrent, as BitTorrent has no concept of state — a distinction that turns out to be crucially important. They are sometimes described as decentralized autonomous

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

New York, Jan. 29, 2024 - (Plato Data) - Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses. The data from the first eighteen participants who received the first six dose levels represented the readout, which was

Bracket Labs Announces $2 Million Pre-Seed Raise to Support the Launch of its ‘Passages’ Trading Platform

PANAMA CITY FLA – January 4, 2024 – Bracket Labs completed a $2 million pre-seed fundraise round to support the launch of "Passage," a volatility trading product available on the project’s BracketX trading platform. The debut of the range-bound product makes trading long and short volatility entirely on-chain easy for traders of all levels. In June 2023, Bracket Labs completed Binance Labs’ Season 5 Incubation Program and received investment from Binance Labs. In addition to completing the Incubation Program, Bracket Labs completed its pre-seed investment round from other notable crypto

Alexa Tsui Appointed Chief Operating Officer of G2Xchange

Alexa Tsui Appointed Chief Operating Officer of G2Xchange Washington DC - G2Xchange, the leader in providing industry news, insights, and market intelligence for the US federal contracting sector, is proud to announce the appointment of Alexa Tsui as its new Chief Operating Officer (COO), effective January 2nd, 2024. Ms. Tsui, a seasoned professional with a career spanning nearly 20 years in leadership roles supporting strategic growth initiatives, brings a wealth of expertise to G2Xchange based on her demonstrated commitment to excellence, her long-standing industry relationships, and a deep understanding of

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Clinical Squared and PlatoHealth Join Forces to Revolutionize Healthcare with Advanced Data Orchestration Powered by AI.

Washington DC, September 20th, 2023 — Clinical Squared (C2) and Platohealth.ai are delighted to announce a groundbreaking partnership that promises to reshape the healthcare landscape. Their collaboration brings together the healthcare expertise of C2 and the cutting-edge AI and machine learning capabilities of Plato.ai to create innovative solutions. [gallery columns="2" link="none" size="large" ids="2281765,2281767"] Clinical Squared, a leader in healthcare market expertise, data architecture, software development, consultation and implementation services, will lend its extensive industry knowledge to Plato.ai's platform. In turn, Plato.ai will provide advanced AI and machine learning mechanisms to

ESG1 Partners with GMEX ZERO13 on Trading Tokenized Carbon Credits from Emissions Removals

Cross-chain interoperable ESG asset trading and settlement enabled by ZERO13 as a fully integrated market distribution partner for ESG1’s highly verified, IoT-linked industrial carbon credit tokens. London and Calgary, 14 September 2023: ZERO13, a GMEX Group initiative providing a digital climate fintech aggregation ecosystem, and ESG1, a subsidiary of GuildOne providing innovative digital assets and ESG solutions built on R3’s Corda, have announced a landmark collaboration that will create an automated digital pipeline for North American industrial carbon offsets to reach high-demand markets in Europe and the Middle East. ESG1’s

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Travelzoo META Opens for Founding Members

NEW YORK/PARIS/TOKYO, May 11, 2023 - (ACN Newswire) - The future of travel is here. After months of anticipation, Travelzoo META, a members-only service offering groundbreaking Metaverse travel experiences, is now accepting its first one million Founding Members. Launched by Travelzoo® (NASDAQ: TZOO), a global Internet media company, Travelzoo META will give Founding Members the opportunity to be the first to experience travel in the Metaverse. Travelzoo META's experiences are intended to allow its members to explore hard-to-reach corners of the world, like summiting Mount Everest, or travel back in time—to